FDA Releases ANDA Submission Guidance
The guidance assists applicants in preparing prior approval supplements for abbreviated new drug applications.
FDA published guidance on Oct. 14, 2016 explaining how the Generic Drug User Fee Amendments of 2012 (GDUFA) relates to preparing prior approval supplements (PASs) and amendments to PASs for abbreviated new drug applications (ANDAs) under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). FDA also describes GDUFA performance metric goals and clarifies how the agency will handle a PAS and PAS amendments for an ANDA subject to those goals.
In the guidance, FDA describes how GDUFA performance metric goals apply to a PAS subject to the refuse-to-receive standards, a PAS that requires an inspection, a PAS for which an inspection is not required, an amendment to a PAS, and other PAS-related matters.
Source: FDA
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
